ReviewJournal of clinical medicine2020
Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far?
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 98 citations in OpenAlex.
- Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial.Obesity (Silver Spring, Md.) · 2023Trial
- Screening of Small Peptide Against Ischemic Fatty-Acid Binding Protein (FABP).The protein journal · 2026Article
- Exploratory Evaluation of Cardiac Fatty Acid-Binding Protein (H-FABP), Troponin I, NT-proBNP, Echocardiography, and Holter Monitoring for the Assessment of Doxorubicin-Induced Cardiac Damage in Dogs.Veterinary sciences · 2026Article
- Myocardial Stress Biomarkers and Inflammatory Indices in Cattle With Bovine Respiratory Disease Complex.Veterinary medicine and science · 2026Article
- Heart-Type Fatty Acid-Binding Protein as a Marker of Subclinical Cardiac Dysfunction and Cardiorenal Interaction in Autosomal Dominant Polycystic Kidney Disease.Life (Basel, Switzerland) · 2026Article
- Myocardial injury associated with naturally occurring clinical bovine anaplasmosis: evaluation of novel cardiac biomarkers.Veterinary research communications · 2026Article
- Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.International journal of molecular sciences · 2026Review
- Cardiac biomarkers in athletes and active individuals: a clinical review of exercise-induced elevations and diagnostic interpretation.Frontiers in physiology · 2026Review
- BUN-albumin ratio as a prognostic marker in decompensated heart failure with reduced ejection fraction.American heart journal plus : cardiology research and practice · 2026Article
- Novel blood biomarkers for heart failure mortality: mechanistic pathways, aging biology, and risk stratification.Frontiers in cardiovascular medicine · 2026Review
- Diagnostic and prognostic utility of heart-type fatty acid binding proteins in cardiovascular diseases and risk factors - an updated review of the literature.International journal of cardiology. Heart & vasculature · 2025Review
- Recent advances in biomarkers for detection and diagnosis of sepsis and organ dysfunction: a comprehensive review.European journal of medical research · 2025Review
- An mTOR-Tfeb-Fabp7a Axis Ameliorates bag3 Cardiomyopathy via Decelerating Cardiac Aging.Aging cell · 2025Article
- Dynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study.Journal of clinical medicine · 2025Article
- Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine.Diagnostics (Basel, Switzerland) · 2025Review
- The Latest Advances in Omics Technology for Assessing Tissue Damage: Implications for the Study of Sudden Cardiac Death.International journal of molecular sciences · 2025Review
- Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis.International journal of molecular sciences · 2025Review
- Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives.Journal of clinical medicine · 2025Review
- H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.Vascular health and risk management · 2025Article
- Recent Advances in Aptamers-Based Nanosystems for Diagnosis and Therapy of Cardiovascular Diseases: An Updated Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) remains one of the leading causes of death to date despite extensive research funding. Various studies are conducted every year in an attempt to improve diagnostic accuracy and therapy monitoring. The small cytoplasmic heart-type fatty acid-binding protein (H-FABP) has been studied in a variety of disease entities. Here, we provide a review of the available literature on H-FABP and its possible applications in HF.
resultsIn total, 23 studies regarding H-FABP in HF were included in this review.
conclusionWhile, algorithms already exist in the area of risk stratification for acute pulmonary embolism, there is still no consensus for the routine use of H-FABP in daily clinical practice in HF. At present, the strongest evidence exists for risk evaluation of adverse cardiac events. Other future applications of H-FABP may include early detection of ischemia, worsening of renal failure, and long-term treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.